May 24, 2023
In this podcast episode, Douglas Rex, MD,
discusses the importance of intent-to-treat for colorectal
screenings, how screening technology has transformed
gastroenterology practice and more.
• Intro :02
• Welcome to this episode of Gut Talk
:23
• The interview/about Rex
:32
• Where did you grow up, and what was your childhood
like? :52
• What got you interested in medicine?
2:50
• How did your journey with GI start?
4:33
• How have those early days and formidable experiences
of being in the lab impacted your career today and what you are
more well-known for? 8:19
• Discussion on the NEJM
study and the
debates surrounding methodologies for endoscopy
11:55
• Rex, Chey and Berry on the importance on the issue
surrounding intent-to-treat in the setting of colorectal cancer
screening 14:57
• Rex on the Multi-Society Task Force of Colorectal
Cancer (MSTF) committee and how they come to decisions that
influence how gastroenterologists practice daily
16:55
• Was it a difficult decision to move the threshold
for colorectal cancer screening from 50 to 45?
20:41
• In an environment where there is a limited resource
such as colonoscopy, are you struggling with volume at your
institution? … What are some strategies that listeners can utilize
to prioritize patients, seek other possibilities and manage volume?
22:28
• What’s the right way to approach the screening
problem? … Where will this lead us ten years from now if all of us
are spending our time in the endoscopy suite because of continued
reduction in the age of screening while the prevalence of
functional conditions and chronic diseases is also rising?
25:51
• How long do you think we’ll continue to rely upon
screening colonoscopy as one of our primary means by which to
screen for colon cancer? Are there any technologies on the horizon
that will eat into the share of screening colonoscopy?
28:55
• What is your perspective on AI and how it can impact
not only adenoma detection rate and polyp detection, but also
clinical workflows such as documentation time? … Are you concerned
about the new generation of clinicians being trained on and relying
on these tools? 34:07
• What have you learned in terms of best practices for
the right and wrong ways to work with industry?
38:07
• Thank you, Dr. Rex
40:25
• Thanks for listening
40:43
Douglas K. Rex,
MD, is a distinguished professor emeritus at Indiana
University School of Medicine and a full-time clinical
gastroenterologist at Indiana University Hospitals.
We’d love to hear from you! Send your comments/questions to
guttalkpodcast@healio.com.
Follow us on Twitter @HealioGastro @sameerkberry @umfoodoc. For more from Dr.
Rex, follow @Rex_colonoscopy
on Twitter.
Disclosures: Chey and Berry report no relevant
financial disclosures. Rex is a consultant for Boston Scientific,
Braintree Laboratories, Medtronic, Norgine, and Olympus
Corporation. He provides research support at Braintree
Laboratories, Erbe USA Inc, Medivators, and Olympus Corporation and
is a shareholder of Satisfai Health.